Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Gains from Investment Securities (2018 - 2026)

Outset Medical (OM) reported Gains from Investment Securities of $85000.0 for Q1 2026, down 98.05% on a QoQ basis from $4.4 million in Q2 2025.

Outset Medical (OM) has 6 years of Gains from Investment Securities data on file, last reported at $85000.0 in Q1 2026.

  • Quarterly Gains from Investment Securities changed N/A year-over-year to $85000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (changed N/A YoY) and the FY2025 annual result came in at $81000.0, down 11.96% from the prior year.
  • Gains from Investment Securities retreated to $85000.0 in Q1 2026 per OM's latest filing, from $4.4 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $4.4 million in Q2 2025 and bottomed at -$528000.0 in Q4 2023.
  • The 3-year median for Gains from Investment Securities is $85000.0 (2026), against an average of $1.3 million.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Outset Medical 90,946.35 -286.55 Mn 12.10 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 85,000.00
Mar 31, 2026 85,000.00
Jun 30, 2025 4.37 Mn
Jun 30, 2025 4.37 Mn
Dec 31, 2023 -528,000.00
Dec 31, 2023 -528,000.00
Dec 31, 2020 8.85 Mn
Dec 31, 2020 8.85 Mn
Sep 30, 2020 1.94 Bn
Sep 30, 2020 1.94 Bn
Jun 30, 2020 8.85 Mn
Jun 30, 2020 8.85 Mn
Mar 31, 2020 3,000.00
Mar 31, 2020 3,000.00
Dec 31, 2019 302,000.00
Dec 31, 2019 302,000.00
Dec 31, 2018 321,000.00
Dec 31, 2018 321,000.00